TF and central nervous system cancer: To validate this cascade, we also utilized PDCs from patients (Glioma #12, 11: patients belong to S-Im and harbored PDGFRA mutations; Glioma #3, 31: patients belong to S-Ne and do not harbored PDGFRA mutations), conducted proteome, phosphoproteome and further applied catTFRE approach to depict TF’s DNA binding activity54 (Methods) in these PDCs (Supplementary Fig. 17A).